Figure 3. Clinically significant bleeding events with clinical implementation of CYP2C19‐guided antiplatelet therapy after PCI.

Weighted data are shown for patients with a CYP2C19 LOF allele treated with clopidogrel (LOF‐clopidogrel) or alternative therapy (LOF‐alternative) and patients without a LOF allele treated with either clopidogrel (non‐LOF‐clopidogrel) or alternative therapy (non‐LOF‐alternative). Note that patients were standardized to 2 different populations based on LOF allele status. The number of patients in each group was slightly different than for the atherothrombotic end point as patients were stratified based on antiplatelet therapy prescribed at the time of the bleeding event or last follow‐up. LOF indicates loss‐of‐function; and PCI, percutaneous coronary intervention.